XVIVO Perfusion AB Publishes Annual Report 2023

04 Apr 2024
www.biospace.com
GOTHENBURG, SWEDEN / ACCESSWIRE / April 4, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today XVIVO Perfusion AB (publ) publish the Annual Report for 2023. The Annual Report is attached to this press release in pdf format and in ESEF format (European Single Electronic Format) and is also available on . April 4, 2024 Gothenburg XVIVO Perfusion AB (publ) Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website . This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-04 18:45 CEST. Attachments XVIVO Perfusion AB (publ) Annual Report 2023 549300G2464FYLS14B41-2023-12-31-sv 549300G2464FYLS14B41_20231231_viewer SOURCE: XVIVO Perfusion AB View the original press release on accesswire.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.